Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 1
Options for Poliomyelitis Vaccination in the United States: Workshop Summary Introduction The Institute of Medicine (IOM) and the Centers for Disease Control and Prevention (CDC) held workshops on poliomyelitis vaccination options on consecutive days, June 7 and June 8, 1995. On the first day, under the auspices of IOM, the options for polio vaccination were presented, with the focus primarily being the available scientific information. On the second day, under the auspices of CDC, the discussion moved to the policy issues inherent in decisions about vaccination strategies, the particular purview of CDC and its Advisory Committee on Immunization Practices (ACIP). This document summarizes the information from the first day of the joint workshops, including the personal experiences of two individuals affected by vaccine-associated polio. To indicate the flavor of the second day's discussion, some direct quotes from that day's panel presentations are interspersed throughout the text of this document. The workshops came about because CDC, through ACIP, asked IOM's Vaccine Safety Forum to sponsor an activity at which the issues surrounding polio vaccination strategies could be discussed in an open setting where ideas could be freely exchanged without the necessity of reaching consensus and making conclusions. IOM's involvement with polio vaccine policy began with a 1977 report in which the study committee recommended the strategy of primary reliance on the oral poliovirus vaccine (OPV), with the use of inactivated poliovirus vaccine (IPV) for adults, in situations in which OPV is contraindicated (e.g., for persons with known immunodeficiencies), and as an option for others. In 1988, another IOM study committee came to the same basic conclusion, with the exception that the use of IPV for primary immunization was to be considered when a combination product made up of diphtheria and tetanus toxoids and
OCR for page 2
Options for Poliomyelitis Vaccination in the United States: Workshop Summary pertussis vaccine (DTP) and IPV became available (estimated at the time to require 2 to 5 years); separate administration of IPV was thought to be too difficult to implement. The combined product is still not available in the United States. The 1988 committee further stated that “If it is demonstrated later that 90 percent or more of preschool children are immune without significant pockets of nonimmune individuals, and wild virus is indeed absent from the environment, the use of OPV might be terminated [replaced by IPV] except in special circumstances . . .” (p. 28). Two major differences affect the current climate of decisionmaking about polio vaccination policy compared with that of earlier years. The first is that poliomyelitis disease from wild virus has been eradicated from the Western Hemisphere. The relatively few cases of polio occurring in the hemisphere are attributable to the live attenuated polio vaccine, OPV. These cases are known as vaccine-associated paralytic polio, or VAPP. Second, incidence of the natural disease has also substantially decreased internationally. However, because natural polio disease has not yet been entirely eliminated from the rest of the world, it is possible for international travelers to bring (import) poliovirus into the country, potentially infecting others and causing disease. The present challenge for policymakers is to decide what action to take until polio disease is eradicated globally. It is to be hoped that the IOM workshop contributed to the ability of policymakers to meet that challenge. Following presentations on the history and the current status of polio vaccines and on the characteristics of the vaccines themselves, discussion at the IOM workshop centered around five options for vaccination against poliomyelitis: (1) primary reliance on OPV, which is the current U.S. policy; (2) primary reliance on IPV; (3) a sequential schedule in which one or more doses of IPV would be followed by one or more doses of OPV; (4) informed parental choice of the polio vaccine that a child would receive; and (5) cessation of vaccination against poliomyelitis. This summary begins with a description of U.S. and international experience with polio vaccination, including the importance of such issues as vaccine-associated polio and the risk of importation of poliovirus. It continues with a description of the presentations and discussion of each of the five options mentioned above. The summary is an attempt at a faithful representation of the activities of the workshop. As mentioned earlier, it does not contain conclusions and recommendations, and it is not intended to be an introduction to or primer on issues of vaccination and immunity. For background information on polio vaccination, and immunization in general, the reader is referred to Plotkin and Mortimer (1994).
Representative terms from entire chapter: